Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Roniciclib |
Synonyms | |
Therapy Description |
Roniciclib (BAY1000394) is a pan-CDK inhibitor that induces cell-cycle arrest and apoptosis, resulting in inhibition of tumor cell growth (PMID: 22821149, PMID: 30677506). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Roniciclib | BAY1000394|BAY10-00394|BAY 10-00394 | CDK Inhibitor (Pan) 3 | Roniciclib (BAY1000394) is a pan-CDK inhibitor that induces cell-cycle arrest and apoptosis, resulting in inhibition of tumor cell growth (PMID: 22821149, PMID: 30677506). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02457351 | Phase I | Roniciclib Itraconazole | Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study | Completed | CAN | 0 |
NCT02161419 | Phase II | Roniciclib | RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer | Terminated | USA | POL | ITA | HUN | FRA | DEU | BEL | 2 |
NCT02656849 | Phase II | Roniciclib | BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors | Withdrawn | USA | 0 |